Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/21
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 12/31/25
End: 11/30/27
Due: 11/30/28
Phase: N/A
Priority: Normal
Start: 07/30/23
End: 09/30/26
Due: 09/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection | NCT04526717 | J Ints Bio | user2@example.com | None | 2021-12-31 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |
| Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies | NCT04294875 | J Ints Bio | user2@example.com | None | 2025-12-31 | 2027-11-30 | 2028-11-30 | - | - | 2025-07-14 |
| A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | NCT05394831 | J Ints Bio | user2@example.com | None | 2023-07-30 | 2026-09-30 | 2027-09-30 | - | - | 2025-07-14 |